Molecular responses to immune checkpoint blockade in glioblastoma

Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma

(2019) Junfei Zhao et al.   NATURE MEDICINE

Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma

(2019) Timothy F. Cloughesy et al.   NATURE MEDICINE

Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma

(2019) Kurt A. Schalper et al.   NATURE MEDICINE

Quo Vadis—Do Immunotherapies Have a Role in Glioblastoma?

(2018) Sylvia C. Kurz et al.   Current Treatment Options in Neurology

CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011–2015

(2018) Quinn T Ostrom et al.   NEURO-ONCOLOGY

Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial

(2018) Derin B. Keskin et al.   NATURE

Viral and other therapies for recurrent glioblastoma: is a 24-month durable response unusual?

(2018) E Antonio Chiocca et al.   NEURO-ONCOLOGY

Treatment of Glioblastoma

(2017) Joo Yeon Nam et al.   Journal of Oncology Practice

Immune modulation associated with vascular endothelial growth factor (VEGF) blockade in patients with glioblastoma

(2016) Alissa A. Thomas et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

The role of CD44 in glioblastoma multiforme

(2016) Kelly L. Mooney et al.   JOURNAL OF CLINICAL NEUROSCIENCE

IDH1andIDH2Mutations in Gliomas

(2009) Hai Yan et al.   NEW ENGLAND JOURNAL OF MEDICINE